Inside GRAPPA

How does multimorbidity impact the progression from psoriasis to psoriatic arthritis? Can early identification of chronic conditions help prevent psoriatic arthritis in high-risk patients?In this episode of Inside GRAPPA, host Dr. Mio Nakamura sits down with Dr. Paras Karmacharya, recipient of a GRAPPA Annual Pilot Research Grant. He presented his findings at the 2024 GRAPPA Annual Meeting in Seattle and shares his groundbreaking study with us on "Multimorbidity and Psoriasis as a Risk Factor for Psoriatic Arthritis." Dr. Karmacharya discusses his personal journey into psoriatic arthritis research, how his study leveraged the Rochester Epidemiology Project, and what the findings mean for the future of patient care. He also explores:  ✔️ What multimorbidity really means in psoriatic disease  ✔️ The connection between chronic conditions and psoriatic arthritis risk  ✔️ How his study design helped uncover key insights  ✔️ The clinical implications for screening, early intervention, and patient educationKey Takeaways  🔹 Multimorbidity matters: Patients with multiple chronic conditions at the time of psoriasis diagnosis had a significantly higher risk of developing psoriatic arthritis.  🔹 Psychiatric and musculoskeletal disorders---such as anxiety, mood disorders, and fibromyalgia---were strongly associated with increased risk.  🔹 A shift in clinical approach is needed: Multidisciplinary care models, early screening, and preventive strategies could improve patient outcomes.Resources & Links  📄 Learn more about GRAPPA's research initiatives: GRAPPA Website  🎧 Listen & subscribe to Inside GRAPPA on your favorite podcast platform.

What if we could predict psoriatic arthritis before it even begins? In this episode of Inside GRAPPA, host Dr. Hanna Johnsson is joined by Professors Oliver Fitzgerald and Steve Pennington to discuss the groundbreaking HIPPOCRATES Project. Funded by the Innovative Healthcare Initiative, this major European research effort is tackling the biggest challenges in psoriatic arthritis (PsA)—from early diagnosis to precision treatment.With 27 partners across academia, industry, and patient organizations, HIPPOCRATES is at the forefront of multi omics research, integrating cutting-edge genomics, proteomics, and imaging technologies to revolutionize PsA care. But what are the biggest hurdles they’ve faced? And how close are they to real-world clinical impact?🔑 Key Takeaways📌 The four major unmet needs in psoriatic arthritis and how HIPPOCRATES is addressing them.📌 How patient representatives are shaping the research and ensuring its relevance.📌 The role of multi omics in predicting PsA progression and improving treatment response.📌 Challenges of coordinating a massive international project and the unexpected roadblocks.📌 Early findings and what they mean for the future of PsA diagnosis and treatment.📢 Resources & Links🔗 Learn more about the HIPPOCRATES Project
🔗 Follow GRAPPA: grappanetwork.org🎧 Listen now on Apple Podcasts, Spotify, or wherever you get your podcasts!💡 Enjoying the podcast? Leave us a review and let us know what topics you’d like to hear next!

In this episode, host Dr. Fabian Proft explores the most impactful research and updates from the EADV 2024 Congress in Amsterdam. Joining him are distinguished Young GRAPPA members Dr. Dimitri Luz, Dr. Ahmet Uğur, and Dr. Margo Gkini, who each share their expert perspectives on groundbreaking studies and their implications for psoriatic disease care.Episode Highlights:What the latest research reveals about psoriasis pathophysiology.  How biologics are impacting long-term treatment safety and efficacy.  Insights into the gut-skin connection and its role in inflammation.Resources and Links:  Learn more about GRAPPA: GRAPPA Official Website  Discover highlights from the GRAPPA EADV 2024 Congress Highlights.🎧 Subscribe to Inside GRAPPA on your favorite podcast platform for more updates on cutting-edge research and clinical strategies in psoriasis and psoriatic arthritis. Don't miss the next episode---stay tuned and stay curious!

How close are we to predicting psoriatic arthritis (PsA) before it strikes? In this episode of Inside GRAPPA, Dr. Fabian Proft sits down with two esteemed researchers, Dr. Axel Svedbom and Professor Mona Ståhle, from the Karolinska Institute in Stockholm, to discuss their groundbreaking study on predicting PsA in patients with new-onset psoriasis. Funded by the GRAPPA Pilot Research Grant, this project is poised to revolutionize early detection and intervention strategies for psoriatic disease.Listen as they discuss:  The innovative predictive models combining machine learning with clinical data.  Key findings, including the significance of arthralgia as a predictive marker for PsA.  How their research could reshape clinical practices and improve patient outcomes.Featured Guests  Dr. Axel Svedbom: Postdoctoral researcher specializing in registry-based research and health economics, with over a decade of focus on psoriasis and psoriatic arthritis.  Professor Mona Ståhle: Dermatologist and researcher dedicated to advancing understanding and treatment of psoriatic disease.Resources & Links  Stay updated with GRAPPA's initiatives: GRAPPA Website.  Explore previous episodes of Inside GRAPPA: Podcast Archive.🎙️ Subscribe to Inside GRAPPA and join the conversation!

How should musculoskeletal symptoms in psoriasis patients be managed---and who should take the lead? In this episode of Inside GRAPPA, Dr. Mio Nakamura moderates a compelling debate featuring Dr. Laura Savage, Consultant Dermatologist from Leeds Teaching Hospital, UK, and Dr. Fabian Proft, Rheumatologist from Berlin, Germany. Together, they tackle the vital question: Should dermatologists or rheumatologists be in the driver's seat when managing psoriatic arthritis (PsA)?Listen as they discuss:  The role of dermatologists in early detection and PsA prevention.    Rheumatologists' emphasis on precise diagnosis and targeted treatment.    The power of collaborative care in improving patient outcomes.Join us for an engaging conversation about the challenges and opportunities in PsA management, and how multidisciplinary approaches can lead to better care for patients with psoriatic disease.Featured Guests  Dr. Laura Savage: Consultant Dermatologist specializing in psoriatic disease, advocating for early intervention strategies in dermatology.    Dr. Fabian Proft: Rheumatologist with expertise in imaging and precision medicine for inflammatory arthritis.Resources & Links  Discover GRAPPA's commitment to collaboration: GRAPPA Website.    Catch up on past episodes of Inside GRAPPA: Podcast Archive.🎙️ Don't miss this episode filled with expert perspectives on psoriatic disease care. Subscribe to Inside GRAPPA and be part of the conversation!

In this insightful episode, host Dr. Sebastian Herrera delves into the critical topic of comorbidities and related conditions in psoriatic disease, alongside experts Professor Kurt de Vlam MD, PhD, Head of Clinic Rheumatology at the University Hospitals Leuven in Belgium and Dr. Alexis Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania in the United States.What's inside this episode?Understanding Comorbidities vs. Related Conditions: Discover the distinctions between these two critical aspects and why it's important to differentiate them in psoriatic disease management.Expert Insights: Hear about the influence of comorbidities on treatment choices and patient outcomes.Impact on Treatment: Learn how related conditions and comorbidities affect therapeutic decisions, including the selection of DMARDs.Patient Care: Explore the importance of a comprehensive approach to treating psoriatic disease, addressing both the primary condition and associated health issues.Key Points & Highlights:Definitions and Importance: Clear definitions of comorbidities and related conditions, and their significance in the clinical setting.Treatment Influences: How the presence of comorbidities can alter the choice of therapies and the necessity of personalized treatment plans.Common Comorbidities: Discussion on obesity, cardiovascular disease, depression, and more, and their implications for patient care.Future Directions: The need for ongoing research and proactive management strategies to improve patient outcomes.Why listen?Educational Insight: Gain a deeper understanding of how comorbidities and related conditions impact psoriatic disease.Expert Opinions: Benefit from the knowledge and experience of leading specialists in the field.Comprehensive Care: Learn about the holistic approach to managing psoriatic disease, ensuring better quality of life for patients.Stay Connected:For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!